ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with a planned invasive strategy, kidney function should not interfere in this decision. 

The main findings of this study were that prasugrel has lower risk of all cause death, MI or stroke, and also had a similar risk of bleeding compared against ticagrelor. These findings were consistent with those of low and intermediate risk patients or high glomerular filtration. 

These findings were presented during the ESC 2021 scientific sessions and were simultaneously published in JACC: Cardiovascular Interventions.

Patients with altered kidney function are challenging for multiple reasons: on the one hand, they present higher ischemic risk and on the one hand, a higher risk of bleeding, given drug pharmacokinetics. 

For this analysis, the authors divided 4,012 participants according to glomerular filtration into 3 groups: low (<60 mL/min/1.73; m2; 760 patients), intermediate (60 to 90 mL/min/1.73 m2; 1968 patients) and high (>90 mL/min/1.73 m2; 1284 patients).

As expected, the worse the glomerular filtration, the bigger the number of events, both ischemic and hemorrhagic.  

However, this did not affect the relative efficacy of prasugrel. Moreover, its biggest advantage was in patients with worse glomerular filtration. 


Read also: ESC 2021 | TOMAHAWK: Angiography After Resuscitated Patients from Out-Of-Hospital Cardiac Arrest with No ST Elevation.


Specifically, in this last subgroup, the rate of all cause death, MI or stroke was significantly higher in patients receiving ticagrelor vs prasugrel (20.5% vs 14.7%; HR 1.47; CI 95% 1.04 to 2.08), with no cost in bleeding BARC 3-5 (10.4% vs 8.4%; HR 1.24; CI 95% 0.73-2.09).

After a few years of absolute dominion of ticagrelor, several studies have slowly brought back prasugrel and clopidogrel to the current clinical arena.  

Original Title: Ticagrelor or prasugrel in patients with acute coronary syndrome in relation to estimated glomerular filtration rate. 

Reference: Wöhrle J. J Am Coll Cardiol Intv. 2021; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...